Phase II trial of panitumumab (P) plus mytomicin C (M), 5-fluorouracil (5-FU), and radiation (RT) in patients with squamous cell carcinoma of the anal canal (SCAC): Safety and efficacy profile—VITAL study, GEMCAD 09-02 clinical trial

Autor:	Rocio Garcia-Carbonero, Ismael Ghanem, Vicente Alonso, Jaime Feliu, Carmen Castanon, Jose Lopez-Torrcilla, Pilar García-Alfonso, Jaume Capdevila, Maria Elena Sanchez, Isabel Sevilla, Juan Maurel, Laura Cerezo, Begona Quintana-Angel, Inmaculada Guasch, Carles Conill, Carlos F. Lopez
Rok vydání:	2014
Předmět:	Oncology Cancer Research medicine.medical_specialty Standard of care business.industry Anal canal medicine.disease_cause Surgery Clinical trial medicine.anatomical_structure Fluorouracil Internal medicine medicine Panitumumab In patient Basal cell KRAS business medicine.drug
Zdroj:	Journal of Clinical Oncology. 32:4034-4034
ISSN:	1527-7755 0732-183X
Popis:	4034 Background: Standard of care for SCAC has remained unchanged over the past 4 decades. More than 80% of these tumors overexpress the EGFR receptor and
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e8b5030d6a34422153599709bc238acb https://doi.org/10.1200/jco.2014.32.15_suppl.4034 Zobrazit plný text záznamu